Video

Treatment of Neuroendocrine Tumor Liver Metastases

For High-Definition, Click

The symptoms associated with hepatic metastatses from a pancreatic neuroendocrine tumor (NET) can be ameliorated through surgical debulking, suggests Rodney F. Pommier, MD. Moreover, an improvement in long-term outcomes can be achieved by an approximate 90% tumor debulking regardless of the margins, unlike other metastatic tumors. In fact, Pommier notes, many metastatic lesions within the liver can be enucleated without causing higher rates of recurrence.

Outside of surgical options, a variety of other treatment approaches can be utilized for patients with liver metastases, including chemoembolization, radioembolization, and ablation. However, these techniques should be considered secondary to surgery, since they may preclude a successful liver operation, Pommier advises. In general, embolization for liver metastases should be reserved for patients with extensive disease that cannot be treated by surgical debulking.

Related Videos
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP
Cindy Medina Pabon, MD, assistant professor, Sylvester Cancer Center, University of Miami; assistant lead, GI Cancer Clinical Research, Gastrointestinal Medical Oncology, University of Miami Health Systems
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss ongoing research in gastrointestinal cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, discuss research building upon approved combinations in unresectable hepatocellular carcinoma.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on trastuzumab deruxtecan–based regimens in advanced HER2-positive GI cancers.
Mohammed Najeeb Al Hallak, MD, MS, and Sakti Chakrabarti, MD, on tremelimumab/durvalumab vs atezolizumab/bevacizumab in unresectable HCC.